Navigation Links
Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
Date:10/25/2007

Cell Therapeutics, Inc. (CTI) announces data presented at AACR-NCI-EORTC

Symposium

SAN FRANCISCO, Oct. 26 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) and Systems Medicine, LLC (SM), a wholly-owned subsidiary of CTI, announced new preclinical data from several of its drug candidates during the 19th annual AACR-NCI-EORTC Symposium.

"These studies show potential progress toward identifying specific tumor types with a higher likelihood of demonstrating response to anti-cancer compounds early in clinical development and are critical to our goal of a highly focused clinical development strategy," said Jack W. Singer, M.D., Chief Medical Officer of CTI.

A new class of thienopyrimidine Src inhibitors demonstrates potent growth suppression of imatinib resistant Ba/F3 cells harboring a wide range of BCR-ABL mutations, including the CML relevant T315I (Abstract #B238)

Spyro Mousses, Ph.D., Senior Investigator and Director, Cancer Drug Development Laboratory at the Translational Genomics Research Institute (TGen) presented preclinical data that showed two thienopyrimidine Src inhibitors work in imantinib-resistant tumors, including the most frequent mutation leading to relapse. The study showed the Src inhibitors retained potent and non-selective cytotoxicity (at sub-micromolar concentrations) in cell lines previously shown to be susceptible and resistant to imatinib, including the T315I mutant cell line. The data suggest that the thienopyrimidine Src inhibitors may represent a new class of drugs with in vitro activity against chronic myelogenous leukemia (CML) variants with BCR-ABL mutations, warranting their exploration as potential new treatments for patients with imatinib-resistant forms of cancer. Preliminary in vitro data suggest these compounds are selective for Src.

"Continued development of these compounds is warranted to more extensively evaluate their selectivit
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...LIN, Mass., Nov. 26 PLC ... today that it has received full approval from the....S. pivotal trial to study the effectiveness of th...therapy in the prevention of Contrast-Induced Neph...C,s request to expand their investigation from the...
(Date:11/25/2008)...e-FirstCall/ -- Poniard,Pharmaceuticals, Inc. (Na...d on,innovative oncology therapies, announced tod...es for its preclinical research programs in order ...e clinical development of picoplatin,its lead pr...cialization of,picoplatin in the treatment of sma...
(Date:11/24/2008)...o,s Pizza (NYSE: DPZ ), the,recognized world le...gh for,the kids of St. Jude Children,s Research H... campaign. Domino,s customers will have the opport...benefit the children of St. Jude.,Donations can b...ng online at, www.dominos.com . The campaign begi...
(Date:11/24/2008).../ -- Schering-Plough Corporation (NYSE: SGP ) to...tive adenosine2a receptor antagonist, met the prim...atients suffering from moderate to severe Parkinso...normal involuntary movements (dyskinesias). The t... 2008 R&D Update meeting being hosted for anal...
Breaking Medicine Technology:PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression 913 1Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression 913 2Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression 913 3ATV Injuries on the Rise 6905 1ATV Injuries on the Rise 6905 2ATV Injuries on the Rise 6905 3Environmental exodus 1331 1Environmental exodus 1331 2Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers Newark Provost Award 6903 1Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers Newark Provost Award 6903 2
...sults Presented At ASCO -- , CHICAGO – June ... interferon alfa-2b in stage III melanoma had a,si...vival (RFS),according to the results of the large...stage III melanoma. Results of the Phase,III study...h and,Treatment of Cancer (EORTC) and supported by...
...007 - MGI Pharma, Inc.,(Nasdaq:MOGN), a biopharmac..., today provided highlights of data presentations ...Oncology (ASCO) Annual,Meeting. Dacogen (decitabin...ncluding the presentation of efficacy data in olde...nd activity,observed in patients with refractory a...
Other Medicine Technology:Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 2Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 3Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 4Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 10
(Date:12/1/2008)... are developing a wide variety of arm, wrist and h...ly described gymnastic-related trauma, according t... the Radiological Society of North America (RSNA)....s unusual and might point to something new going o...thletes in different ways," said the study,s lead ...
(Date:12/1/2008)...n the Dec. 1 issue of the journal Sleep is the f...exposure strongly modify sleep patterns in preterm...or developmental difficulties that could persist t... indicate that preterm neonates born to heavy-smok... day displayed disrupted sleep structure and sleep...
(Date:11/30/2008)...Newswire/ -- Combining an ultrasound-guided techni... at relieving the common and painful foot problem ...sented today at the annual meeting of the Radiolog..."There is no widely accepted therapy or standard o...l to relieve the pain of plantar fasciitis," said ...
(Date:11/30/2008)... 1 Faint magnetic,sign...ow that those children,process sound and language...ng,and classifying these brain response patterns ... autism and possibly aid in developing more effect... Timing appears to be crucial. "Children wit...
Breaking Medicine News(10 mins):Health News:MRI shows new types of injuries in young gymnasts 2Health News:High levels of prenatal smoking exposure affect sleep patterns in preterm neonates 2Health News:High levels of prenatal smoking exposure affect sleep patterns in preterm neonates 3Health News:New Treatment Eliminates Heel Pain Caused by Plantar Fasciitis 2Health News:New Treatment Eliminates Heel Pain Caused by Plantar Fasciitis 3Health News:Brain's Magnetic Fields Reveal Language Delays in Autism 2Health News:Brain's Magnetic Fields Reveal Language Delays in Autism 3
...neers have announced that they have created a comp...he topical microbicides// used by women for preven...cides are needed since the infections globally are... physics and chemistry, the researchers developed ...
...ren's Research Hospital have discovered that a pro...on of a molecule that is key to the ability// of r...break down toxins, and of cells to extract energy ...ators showed that ABCB6 is lodged within the outer...
...hat twins are performing on par with other childre...y the performance of the twins// has been found wa...e students. Researchers felt this was because twin...as well as have low educational motivation. The D...
...ates among younger and older Americans have been d...news: No one really knows why// . Those are the f... University of South Carolina and released Thursda... issue of the American Journal of Public Health. ...
Other Medicine News:Health News:Computer Tool Predicts Effectiveness Of Microbicides 2Health News:Computer Tool Predicts Effectiveness Of Microbicides 3Health News:ABCB6 Is Key to Production of Heme in Hemoglobin 2Health News:Most Suicide Rates Decline, but Findings Are Puzzling 2Health News:Most Suicide Rates Decline, but Findings Are Puzzling 3
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: